Dr. Pasha Sarraf has extensive experience in creating value from challenging scientific ideas through imagining, team building, and decision making, with a strategic mind and eye on impactful therapeutic products. He leads Celosia’s team and focuses its portfolio on exceptional ideas that can deliver outsized scientific, medical and economic value.

Pasha spent a decade serving a diverse base of clients at McKinsey & Company as a Partner and Co-leader in the life sciences practices, leading on life sciences strategy, diligence, and forecasting. He later joined Leerink Partners as a Managing Director and Senior Analyst, providing frameworks for valuation and insightful analysis on companies targeting autoimmune disorders and metabolic diseases. Subsequently, Pasha joined Flagship Pioneering as an Operating Partner, where he led and directed a world-class team of computational scientists and stem cell biologists, together proposed a prescient approach to genetic based target discovery, used it to identify a completely novel genetic circuit in Parkinson’s disease, and initiated a drug discovery program for an innovative target that was later licensed by GSK. Following Flagship, Pasha joined Matterhorn Biosciences as CEO and executive board member, where he built and led a interdisciplinary team who scaled and demonstrated the value of Matterhorn's TCR-based platform.

Pasha has a Bachelor of Science of Engineering from Duke where he majored in biomedical engineering and wrote a thesis on fluid dynamics of blood flow.  He obtained his MD, PhD at Harvard Medical School, where he also won a Howard Hughes fellowship to study at the surgery branch of the NCI and subsequently trained in cell biology at the Dana Farber Cancer Institute. He performed his medical training in internal medicine and rheumatology at Massachusetts General Hospital (MGH) and completed additional fellowships managing complex rheumatological patients at NIAID and NIAMS at the National Institutes of Health (NIH), where he cared for patients with vasculitis, scleroderma, and genetic inflammatory disorders. He has authored more than 50 publications and filed multiple patents for novel therapies and molecular targets.

In addition to his current leadership of Celosia, Pasha is board chairman for Cue Biopharma and Praesidia Biotherapeutics, and a board director for PolarityBio.